Vanassche 2020.

Study name	A randomized, open‐label, adaptive, proof‐of‐concept clinical trial of modulation of host thromboinflammatory response in patients with COVID‐19: the DAWn‐Antico study
Starting date	25/jun/2020
Contact information	Caroline Devooght    Herestraat 49 3000 Leuven Belgium caroline.devooght@uzleuven.be
Methods	Multicentre, open‐label, randomised clinical trial
Participants	210 participants, ≥ 18 years, female and male Male or non‐pregnant female adult ≥ 18 years of age at the time of enrolment, participants eligible for inclusion are hospitalised, adult patients with confirmed and severe COVID‐19
Interventions	We compare LMWHs at 50 IU anti‐Xa/kg twice daily—or 75 IU anti‐Xa twice daily for ICU patients—in combination with aprotinin to standard thromboprophylaxis in hospitalised COVID‐19 patients
Outcomes	Primary Time from day 0 to sustained clinical improvement or live discharge, whichever comes first, whereby a sustained clinical improvement is defined as an improvement of > 2 points vs the highest value of days 0 and 1 and sustained for at least 3 days
Notes	EUCTR2020‐001739‐28‐BE | No data provided